Immunotherapy targeting the programmed cell death protein-1 (PD-1)--programmed cell death ligand-1 (PDL-1) axis in sepsis is poised for clinical trials, although optimal inclusion criteria and predictors of response are not well characterized.

We evaluated the kinetics of soluble (s)PD-1 and sPD-L1 in 30 septic intensive care unit (ICU) patients and 30 nonseptic ICU patients (Table [1](#Tab1){ref-type="table"}). sPD-1 and sPD-L1 were significantly elevated among the septic cohort compared with the nonseptic ICU patients at enrollment (17.7 pg/ml vs. 4.5 pg/ml, *p* = 0.002; and 29.9 pg/ml vs. 11.3 pg/ml, *p* = 0.02; respectively) and were associated with sepsis (Fig. [1](#Fig1){ref-type="fig"}). Higher sPD-L1 on day 3 was associated with mortality among septic patients (16.7 pg/ml vs. 3.0 pg/ml, *p* = 0.054) and also in the total ICU cohort (14.9 pg/ml vs. 2.7 pg/ml, *p* = 0.026). Soluble PD-L1 regressed on interleukin (IL)-6 and interferon (IFN)γ levels were significantly associated in the total ICU cohort and septic patients, possibly pointing to upstream triggers for post-transcriptional modifications. Tumor necrosis factor (TNF)α regressed on sPD-1 and sPD-L1 was significant in all populations including septic survivors, revealing possible downstream effects of sPD-1 and sPD-L1. Initial sPD-1 levels correlated with a drop in lymphocyte count to \< 1 × 10^9^/L (area under the receiver operating characteristic (ROC) curve 0.72, *p* = 0.006) and to \< 0.6 × 10^9^/L (area under the ROC curve 0.68, *p* = 0.02). sPD-L1 also correlated with lymphocyte count drop to \< 1 × 10^9^/L during the hospital stay. The correlation between the two immune checkpoint molecules, sPD-1 and sPD-L1, was also significant on enrollment, and at days 1 and 3 (*p* \< 0.001, *p* \< 0.001, *p* = 0.004, respectively; Fig. [2](#Fig2){ref-type="fig"}).Fig. 1The area under the ROC curve for the discrimination of sepsis by soluble programmed death protein-1 (sPD-1) and soluble programmed death ligand-1 (sPD-L1). These are the day 0 area under the ROC curves for Sequential Organ Function Assessment (SOFA) score, sPD-1 (pg/ml), and sPD-L1 (pg/ml) for the discrimination of patients who have sepsis. Soluble PD-L1 outperforms sPD-1 for discrimination of sepsisTable 1Patient characteristicsVariablesSeptic patients (*n* = 30)Control subjects (*n* = 30) Age (years), median (IQR)63.3 (49.3--74.1)58.6 (52.8--64.6) Male, *n* (%)11 (36)19 (63) White, *n* (%)23 (76)25 (83)Past medical history COPD/asthma/fibrosis, *n* (%)11 (36)2 (7) CAD/MI, CHF, AF, *n* (%)16 (53)7 (23) Diabetes mellitus, *n* (%)5 (17)10 (33) Malignancy, *n* (%)8 (27)6 (20) CKD/ESRD, *n* (%)5 (17)1 (3) Cirrhosis, *n* (%)0 (0)4 (13) Connective tissue disease, *n* (%)3 (10)0 Arthritis, *n* (%)3 (10)3 (10)Clinical assessment WBC (×10^−9^/L), median (IQR)12.8 (6.9--19.1)9.1 (7.6--10.9) SOFA score, median (IQR)7 (5--9)2 (1--4) Shock, *n* (%)24 (80)2 (6)Site of infection in septic patients (*n*) Pneumonia13 Genitourinary tract infection11 Abdominal infection2 Meningitis1 Multiple sites of infection1 Bacteremia9 Unknown1Organism of infection if known in septic patients (*n*) *Escherichia coli* not extended-spectrum β-lactamase producer4 *Escherichia coli* extended-spectrum β-lactamase producer2 Enterobacter1 *Enterococcus faecalis*1 *Acinetobacter baumannii*1 *Pseudomonas aeruginosa*1 Methicillin-resistant *Staphylococcus aureus*1 Methicillin-sensitive *Staphylococcus aureus*1 *Candida albicans*1 *Haemophilus influenzae*1 Bacillus species not anthracis2 *Klebsiella pneumoniae*1*AF* atrial fibrillation, *COPD* chronic obstructive pulmonary disease, *CAD* coronary artery disease, *CHF* congestive heart Failure, *CKD* chronic kidney disease, *ESRD* end-stage renal disease, *IQR* interquartile range, *MI* myocardial infarction, *SOFA* sequential organ function assessment, *WBC* white blood cellFig. 2Correlation between soluble programmed death protein-1 (sPD-1) and soluble programmed death ligand-1 (sPD-L1) on day 0 among all ICU patients. The Pearson correlation between sPD-L1 (pg/ml on *y* axis) and sPD-1 (pg/ml on *x* axis) is 0.629 at the time of enrollment

sPD-1 and sPD-L1 are easily sampled, making them advantageous biomarkers in sepsis. A recent study demonstrated elevated sPD-1 among patients with infected pancreatitis \[[@CR1]\]. sPD-1 may serve as an indicator of severity of sepsis among emergency room patients \[[@CR2]\]. Lange et al. \[[@CR3]\] reported that sPD-1 levels did not differ significantly between septic and nonseptic critically ill patients and had no association with outcome among septic patients. Our results may stem from sampling a different population to Lange and colleagues. Our controls, while critically ill, had lower severity of illness and mortality. Additionally, we excluded patients with immunocompromise, malignancy, and organ transplantation due to possible iatrogenic skewing of sPD-1 and sPD-L1. Approximately half of the control group in Lange et al. developed infections; thus, observations comparing sepsis versus nonseptic groups were limited to initial measurement only.

sPD-1 and sPD-L1 are point-of-care tests that might eventually guide personalized medicine in sepsis. These soluble immune checkpoints can risk-stratify patients for immunotherapy in sepsis and may potentially serve as targets themselves.

ICU

:   Intensive care unit

IFN

:   Interferon

IL

:   Interleukin

PD-1

:   Programmed cell death protein-1

PD-L1

:   Programmed cell death ligand-1

ROC

:   Receiver operator characteristic

TNF

:   Tumor necrosis factor

We would like to thank all the participants in this study.

Funding {#FPar1}
=======

This work was funded in part by the National Institute of General Medical Sciences (GR5223260.1001). GSP received funding to support statistical analyses for this project from Rhode Island Hospital.

Availability of data and materials {#FPar2}
==================================

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

MML and SO constructed the biorepository for this study. DB contributed to the IRB for this study and handling of specimens. TW enrolled patients and collected biosamples and AP supervised biobank maintenance. RZ performed the multiplex analysis. GSP performed the statistical analysis for this project, GSP and SM created the figures presented. DB drafted and edited the manuscript, while SM, SO, GSP, and MML edited and finalized the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate {#FPar3}
==========================================

This study was approved by the Rhode Island Hospital IRB 4159-14. All participants consented prior to enrollment.

Competing interests {#FPar4}
===================

The authors declare that they have no competing interests.

Publisher's Note {#FPar5}
================

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
